Sodium glycerophosphate
Identification
- Name
- Sodium glycerophosphate
- Accession Number
- DB09561
- Description
Sodium glycerophosphate is one of several glycerophosphate salts. It is used clinically to treat or prevent low phosphate levels Label. Glycerophosphate is hydrolyzed to inorganic phosphate and glycerol in the body 1. The extent of this reaction is dependent on the activity of serum alkaline phosphatases.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Sodium glycerophosphate (DB09561)
- Weight
- Average: 216.036
Monoisotopic: 215.9775635 - Chemical Formula
- C3H7Na2O6P
- Synonyms
- Disodium glycerol phosphate
- Sodium glycerophosphate anhydrous
Pharmacology
- Indication
Sodium glycerophosphate is indicated for use as a source of phosphate in total parenteral nutrition Label. It is used in combination with amino acids, dextrose, lipid emulsions, and other electrolytes.
- Associated Therapies
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
Glycerophosphate acts as a source of inorganic phosphate through hydrolysis 1.
- Mechanism of action
Sodium glycerophosphate acts as a donor of inorganic phosphate 1. See Monopotassium phosphate for a description of phosphate's role in the body.
- Absorption
Peak serum phosphate concentration is reached in 4h 1.
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
Glycerophosphate is hydrolyzed to form inorganic phosphate 1. The extent of this reaction is dependent on serum alkaline phosphatase activity.
- Route of elimination
Inorganic phosphate produced is eliminated in the urine 1. There may be a very small amount of glycerophosphate excreted in the urine unchanged.
- Half-life
Inorganic phosphate has a half-life of elimination of 2.06h 1.
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Purchasing individual compounds or compound libraries for your research?
Learn More- Product Ingredients
Ingredient UNII CAS InChI Key Sodium glycerophosphate hydrate RCS9EQ01V4 55073-41-1 OFNNKPAERNWEDD-UHFFFAOYSA-L - Active Moieties
Name Kind UNII CAS InChI Key Sodium cation ionic LYR4M0NH37 17341-25-2 FKNQFGJONOIPTF-UHFFFAOYSA-N - International/Other Brands
- Glycophos (Fresenius Kabi Norge)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Unlock Additional DataGlycophos Injection, solution 216 mg/1mL Intravenous Fresenius Kabi USA, LLC 2013-05-13 Not applicable US 
Additional Data Available- Application NumberApplication NumberAvailable for Purchase
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct CodeAvailable for Purchase
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Hemarexin Liquid and Drinkable Ampoules Sodium glycerophosphate (3.65 mg) + Riboflavin 5'-phosphate sodium (1 mg) + Nicotinamide (10 mg) + Thiamine (1 mg) Liquid Oral Sabex Inc 1997-08-19 2009-11-26 Canada 
Kabiven Sodium glycerophosphate (147 mg/100mL) + Alanine (467 mg/100mL) + Arginine (330 mg/100mL) + Aspartic acid (99 mg/100mL) + Calcium chloride dihydrate (29 mg/100mL) + D-glucose monohydrate (9.8 g/100mL) + Glutamic acid (164 mg/100mL) + Glycine (231 mg/100mL) + Histidine (199 mg/100mL) + Isoleucine (164 mg/100mL) + L-Lysine hydrochloride (263 mg/100mL) + Leucine (231 mg/100mL) + Magnesium sulfate heptahydrate (96 mg/100mL) + Methionine (164 mg/100mL) + Phenylalanine (231 mg/100mL) + Potassium chloride (174 mg/100mL) + Proline (199 mg/100mL) + Serine (131 mg/100mL) + Sodium acetate trihydrate (239 mg/100mL) + Soybean oil (3.9 g/100mL) + Threonine (164 mg/100mL) + Tryptophan (55 mg/100mL) + Tyrosine (6.7 mg/100mL) + Valine (213 mg/100mL) Injection, emulsion Intravenous Fresenius Kabi USA, LLC 2014-08-25 Not applicable US Olimel 3.3% E Sodium glycerophosphate (3.67 g) + Alanine (4.76 g) + Arginine (3.22 g) + Aspartic acid (0.95 g) + Calcium chloride (0.52 g) + Dextrose, unspecified form (126.5 g) + Glutamic acid (1.64 g) + Glycine (2.28 g) + Histidine (1.96 g) + Isoleucine (1.64 g) + L-Lysine acetate (2.59 g) + Leucine (2.28 g) + Magnesium chloride (0.81 g) + Methionine (1.64 g) + Olive oil (32 g) + Phenylalanine (2.28 g) + Potassium chloride (2.24 g) + Proline (1.96 g) + Serine (1.30 g) + Sodium acetate trihydrate (1.50 g) + Soybean oil (8 g) + Threonine (1.64 g) + Tryptophan (0.55 g) + Tyrosine (0.08 g) + Valine (2.1 g) Emulsion Intravenous Baxter Laboratories Not applicable Not applicable Canada Olimel 4.4% E Sodium glycerophosphate (3.67 g) + Alanine (6.41 g) + Arginine (4.34 g) + Aspartic acid (1.28 g) + Calcium chloride (0.52 g) + Dextrose, unspecified form (154 g) + Glutamic acid (2.21 g) + Glycine (3.07 g) + Histidine (2.64 g) + Isoleucine (2.21 g) + L-Lysine acetate (3.48 g) + Leucine (3.07 g) + Magnesium chloride (0.81 g) + Methionine (2.21 g) + Olive oil (32 g) + Phenylalanine (3.07 g) + Potassium chloride (2.24 g) + Proline (2.64 g) + Serine (1.75 g) + Sodium acetate trihydrate (1.50 g) + Soybean oil (8 g) + Threonine (2.21 g) + Tryptophan (0.74 g) + Tyrosine (0.11 g) + Valine (2.83 g) Emulsion Intravenous Baxter Laboratories 2011-02-26 Not applicable Canada Olimel 5.7% E Sodium glycerophosphate (3.67 g) + Alanine (8.24 g) + Arginine (5.58 g) + Aspartic acid (1.65 g) + Calcium chloride (0.52 g) + Dextrose, unspecified form (121 g) + Glutamic acid (2.84 g) + Glycine (3.95 g) + Histidine (3.40 g) + Isoleucine (2.84 g) + L-Lysine acetate (4.48 g) + Leucine (3.95 g) + Magnesium chloride (0.81 g) + Methionine (2.84 g) + Olive oil (32 g) + Phenylalanine (3.95 g) + Potassium chloride (2.24 g) + Proline (3.40 g) + Serine (2.25 g) + Sodium acetate trihydrate (1.50 g) + Soybean oil (8 g) + Threonine (2.84 g) + Tryptophan (0.95 g) + Tyrosine (0.15 g) + Valine (3.64 g) Emulsion Intravenous Baxter Laboratories 2011-01-19 Not applicable Canada Olimel 7.6% E Sodium glycerophosphate (3.67 g) + Alanine (10.99 g) + Arginine (7.44 g) + Aspartic acid (2.2 g) + Calcium chloride (0.52 g) + Dextrose, unspecified form (80.67 g) + Glutamic acid (3.79 g) + Glycine (5.26 g) + Histidine (4.53 g) + Isoleucine (3.79 g) + L-Lysine acetate (5.97 g) + Leucine (5.26 g) + Magnesium chloride (0.81 g) + Methionine (3.79 g) + Olive oil (28 g) + Phenylalanine (5.26 g) + Potassium chloride (2.24 g) + Proline (4.53 g) + Serine (3 g) + Sodium acetate trihydrate (1.5 g) + Soybean oil (7 g) + Threonine (3.79 g) + Tryptophan (1.26 g) + Tyrosine (0.2 g) + Valine (4.86 g) Emulsion Intravenous Baxter Laboratories 2018-10-25 Not applicable Canada Perikabiven Sodium glycerophosphate (105 mg/100mL) + Alanine (333 mg/100mL) + Arginine (235 mg/100mL) + Aspartic acid (71 mg/100mL) + Calcium chloride dihydrate (20 mg/100mL) + D-glucose monohydrate (6.8 g/100mL) + Glutamic acid (116 mg/100mL) + Glycine (164 mg/100mL) + Histidine (141 mg/100mL) + Isoleucine (116 mg/100mL) + L-Lysine hydrochloride (187 mg/100mL) + Leucine (164 mg/100mL) + Magnesium sulfate heptahydrate (68 mg/100mL) + Methionine (116 mg/100mL) + Phenylalanine (164 mg/100mL) + Potassium chloride (174 mg/100mL) + Proline (141 mg/100mL) + Serine (94 mg/100mL) + Sodium acetate trihydrate (170 mg/100mL) + Soybean oil (3.5 g/100mL) + Threonine (116 mg/100mL) + Tryptophan (40 mg/100mL) + Tyrosine (4.8 mg/100mL) + Valine (152 mg/100mL) Injection, emulsion Intravenous Fresenius Kabi USA, LLC 2014-08-25 Not applicable US Periolimel 2.5% E Sodium glycerophosphate (1.91 g) + Alanine (3.66 g) + Arginine (2.48 g) + Aspartic acid (0.73 g) + Calcium chloride (0.30 g) + Dextrose, unspecified form (82.50 g) + Glutamic acid (1.26 g) + Glycine (1.76 g) + Histidine (1.51 g) + Isoleucine (1.26 g) + L-Lysine acetate (1.99 g) + Leucine (1.76 g) + Magnesium chloride (0.45 g) + Methionine (1.26 g) + Olive oil (24 g) + Phenylalanine (1.76 g) + Potassium chloride (1.19 g) + Proline (1.51 g) + Serine (1.0 g) + Sodium acetate trihydrate (1.16 g) + Soybean oil (6 g) + Threonine (1.26 g) + Tryptophan (0.42 g) + Tyrosine (0.06 g) + Valine (1.62 g) Emulsion Intravenous Baxter Laboratories 2011-02-28 Not applicable Canada Smofkabiven Sodium glycerophosphate (0.21 g) + Alanine (0.71 g) + Arginine (0.61 g) + Calcium chloride (0.028 g) + Dextrose, unspecified form (12.7 g) + Fish oil (0.57 g) + Glycine (0.56 g) + Histidine (0.15 g) + Isoleucine (0.25 g) + L-Lysine (0.34 g) + Leucine (0.38 g) + Magnesium sulfate (0.061 g) + Medium-chain triglycerides (1.14 g) + Methionine (0.22 g) + Nitrogen (0.8 g) + Olive oil (0.95 g) + Phenylalanine (0.26 g) + Potassium chloride (0.23 g) + Proline (0.57 g) + Serine (0.33 g) + Sodium acetate trihydrate (0.17 g) + Soybean oil (1.14 g) + Taurine (0.05 g) + Threonine (0.22 g) + Tryptophan (0.10 g) + Tyrosine (0.02 g) + Valine (0.31 g) + Zinc sulfate heptahydrate (0.00066 g) Emulsion Intravenous Fresenius Kabi 2015-09-15 Not applicable Canada Smofkabiven Extra Nitrogen Sodium glycerophosphate (0.23 g) + Alanine (0.92 g) + Arginine (0.79 g) + Calcium chloride (0.028 g) + Dextrose, unspecified form (8.5 g) + Fish oil (0.43 g) + Glycine (0.72 g) + Histidine (0.2 g) + Isoleucine (0.33 g) + L-Lysine (0.43 g) + Leucine (0.48 g) + Magnesium sulfate (0.061 g) + Medium-chain triglycerides (0.87 g) + Methionine (0.28 g) + Nitrogen (1.1 g) + Olive oil (0.72 g) + Phenylalanine (0.33 g) + Potassium chloride (0.23 g) + Proline (0.73 g) + Serine (0.43 g) + Sodium acetate (0.16 g) + Soybean oil (0.87 g) + Taurine (0.065 g) + Threonine (0.29 g) + Tryptophan (0.13 g) + Tyrosine (0.026 g) + Valine (0.41 g) + Zinc sulfate heptahydrate (0.00066 g) Emulsion Intravenous Fresenius Kabi Not applicable Not applicable Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Glycophos Sodium glycerophosphate (216 mg/1mL) Injection, solution Intravenous Fresenius Kabi USA, LLC 2013-05-13 Not applicable US
Categories
- ATC Codes
- B05XA14 — Sodium glycerophosphate
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as glycerophosphates. These are compounds containing a glycerol linked to a phosphate group.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Glycerophospholipids
- Sub Class
- Glycerophosphates
- Direct Parent
- Glycerophosphates
- Alternative Parents
- Alkyl phosphates / Secondary alcohols / 1,2-diols / Primary alcohols / Organic sodium salts / Organic oxides / Hydrocarbon derivatives
- Substituents
- 1,2-diol / Alcohol / Aliphatic acyclic compound / Alkyl phosphate / Hydrocarbon derivative / Organic alkali metal salt / Organic oxide / Organic oxygen compound / Organic phosphoric acid derivative / Organic salt
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- Not Available
Chemical Identifiers
- UNII
- YP1H63LJ2K
- CAS number
- 1334-74-3
- InChI Key
- GEKBIENFFVFKRG-UHFFFAOYSA-L
- InChI
- InChI=1S/C3H9O6P.2Na/c4-1-3(5)2-9-10(6,7)8;;/h3-5H,1-2H2,(H2,6,7,8);;/q;2*+1/p-2
- IUPAC Name
- disodium 3-(phosphonooxy)propane-1,2-diol
- SMILES
- [Na+].[Na+].OCC(O)COP([O-])([O-])=O
References
- General References
- Topp H, Hochfeld O, Bark S, Grossmann M, Joukhadar C, Westphal M, Straatsma H, Rothenburger M: Glycerophosphate is interchangeable with inorganic phosphate in terms of safety and serum pharmacokinetics. Pharmacology. 2011;88(3-4):193-200. doi: 10.1159/000331341. Epub 2011 Oct 4. [PubMed:21986180]
- External Links
- PubChem Compound
- 22251426
- PubChem Substance
- 347827880
- ChemSpider
- 14071
- 1595589
- ChEMBL
- CHEMBL3040581
- FDA label
- Download (806 KB)
- MSDS
- Download (46.7 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Not Yet Recruiting Diagnostic Hypophosphatemia 1 4 Terminated Supportive Care Cancer-related Malnutrition 1 4 Terminated Supportive Care Illness, Critical 1 4 Withdrawn Supportive Care Malnutrition 1 3 Completed Treatment General Surgery / Parenteral Feeding 1 3 Completed Treatment General Surgery / Parenteral Nutrition 1 3 Completed Treatment Parents 2 3 Terminated Treatment Malignant Neoplasm of Pancreas 1 Not Available Recruiting Treatment Malignancies, Hematologic 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution Intravenous 2.5 g/500mL Solution Intravenous 2.55 g/L Solution Intravenous 0.61 g/L Solution Intravenous 1.79 g/L Solution Intravenous 1.66 g/L Emulsion Parenteral 3.99 g/1085ml Emulsion Parenteral 2.05 g/1085ml Injection, solution Intramuscular 100 mg/2ml Syrup Oral 10 mg/ml Tablet Oral 40 MG Injection, solution Intravenous 216 mg/1mL Injection, solution, concentrate Intravenous 216 mg/1mL Injection, solution, concentrate Intravenous 6 g/20ml Injection, solution Intravenous 216 mg/mL Solution Intravenous 216 mg Injection, emulsion Intravenous Injection, emulsion Intravenous 467 mg/100mL Injection Intravenous 110 g Injection Intravenous 165 g Injection Intravenous 220 g Injection Intravenous 275 g Injection Intravenous 107 g Injection Intravenous 143 g Injection Intravenous 178 g Solution Intravenous 16 g/L Injection, emulsion Parenteral 2.33 g Injection, emulsion Intravenous 1.03 g Injection, emulsion Intravenous 1.83 g Emulsion Intravenous 1.83 g Injection Intravenous 1.03 g Injection, emulsion Intravenous 1.6 g/100mL Injection, emulsion; injection, solution Intravenous 3.2 g/100mL Injection, emulsion Intravenous 12 g/1500ml Injection, emulsion Intravenous 32 g/1000ml Injection, emulsion Intravenous 0.52 g/1000ml Injection, emulsion Intravenous 0.42 g/1000ml Injection, emulsion Intravenous 1.6 g Injection Intravenous 2.27 g/l Injection Intravenous 4.12 g/l Solution Intravenous 7.14 g Solution Intravenous 9.52 g Solution Intravenous 11.9 g Emulsion Intravenous 6.41 g Emulsion Intravenous 9.61 g Emulsion Intravenous 12.82 g Injection, emulsion Intravenous 6.41 g/1000ml Emulsion Intravenous 4 g Injection, emulsion Intravenous 8.24 g/1000ml Emulsion Parenteral 1.26 g Emulsion Intravenous Emulsion Intravenous 3 g Injection, emulsion Intravenous 3.66 g Injection, emulsion Intravenous 5.5 g Injection, emulsion Intravenous 7.33 g Injection, emulsion Intravenous 9.16 g Injection, emulsion Intravenous 3.66 g/1000ml Solution Intravenous 3.2 g/100mL Solution Intravenous 1.6 g/100mL Emulsion Parenteral 1.6 g/l Emulsion Parenteral 0.61 g/l Emulsion Parenteral 440 mg Injection, emulsion Intravenous 4.4 g/1000ml Emulsion Parenteral 3.1 g Injection, emulsion Intravenous 7.1 g/1000ml Emulsion Parenteral 50 g Emulsion Parenteral 0.28 g Emulsion Parenteral 0.18 g Liquid Oral Emulsion Parenteral 2.24 g Emulsion Parenteral 4.34 g Emulsion Parenteral 3.95 g Emulsion Parenteral 28 g/1000ml - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source water solubility Soluble MSDS - Predicted Properties
Property Value Source Water Solubility 81.5 mg/mL ALOGPS logP -1.4 ALOGPS logP -2 ChemAxon logS -0.42 ALOGPS pKa (Strongest Acidic) 1.51 ChemAxon pKa (Strongest Basic) -3 ChemAxon Physiological Charge -2 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 112.88 Å2 ChemAxon Rotatable Bond Count 4 ChemAxon Refractivity 29.15 m3·mol-1 ChemAxon Polarizability 12.87 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created on November 30, 2015 12:10 / Updated on June 12, 2020 10:52
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
![]({"CS-Molecular-Health-1.jpg":"/assets/linkouts/CS-Molecular-Health-1-19e76f023997d5ac198da2cb9976457f7b9ba733f0ea8a780fe21191c759e8fa.jpg","Drug-Dev-2.jpg":"/assets/linkouts/Drug-Dev-2-7c3039d93245f493c23278efbf759e4f933848a676262d579087d5cc516af179.jpg","Drug-Search-3.jpg":"/assets/linkouts/Drug-Search-3-7346c33d2133f62b46cbfbbe2b666e78f955c6847e242692c6081fec37c4d10d.jpg","PM-3.jpg":"/assets/linkouts/PM-3-13494ac4c996d71619127a11f685681418d4280832dec162c0b2c9c8bc2eda50.jpg","OD-Webinar-1.jpg":"/assets/linkouts/OD-Webinar-1-f9357f6d57fef5e411aa1c0439ef46c86d9151214434659d096eeed6407b799b.jpg","DDI-3.jpg":"/assets/linkouts/DDI-3-12808cf864d540ad43757b10b08fc52ae93e793b0c6e81345555187b2840ad09.jpg","EMR-2.jpg":"/assets/linkouts/EMR-2-adacf8de3f42cb06d6676d06fce611c29781db6ad30776cd18b72a7d8e69f0c8.jpg","Covid.jpg":"/assets/linkouts/Covid-eed8f17668b0308db62ce3c656f5e2f562376e9185ae08dda5ce6ed9ab0bbd1f.jpg","CS-Molecular-Health-2.jpg":"/assets/linkouts/CS-Molecular-Health-2-22f41f94b3f87e44a1dcaa8f6c03dc411ab69558efd4f3148ff9bb6adaa956dc.jpg","PM-5.jpg":"/assets/linkouts/PM-5-d0dc031e0fa0d0097d912eff07b7e80b27b867264dd5b055e379a57bfa2a8723.jpg","DDI-4.jpg":"/assets/linkouts/DDI-4-313b9c374b937fd78bb2ade652b9b030abb9e6cb90efd35833f793e384e8185b.jpg","Discover-1.jpg":"/assets/linkouts/Discover-1-b48ae6a3872eeb442f4c22a9a1d867428c83a917ec78a8c3ff4e02f84c5d4fef.jpg","Discover-2.jpg":"/assets/linkouts/Discover-2-6e7759998ee0fdc234cd84eea962f2480f0c7dafadabd785924918420decb102.jpg","Repurpose-1.jpg":"/assets/linkouts/Repurpose-1-265fbec40f0eac18d51d3ec4f558c10cb623d834ea75e0296259e458b72ee6d4.jpg","Repurpose-2.jpg":"/assets/linkouts/Repurpose-2-d12bd1d18b92d36eab60e71e6fd59acf04ef60a53783570e11eef397a0e0f4f5.jpg","PM-6.jpg":"/assets/linkouts/PM-6-3ae66e41f7ae1e851a0910be89141cf2533509b46df6379464efc885d5ee2f07.jpg","Drug-Search-4.jpg":"/assets/linkouts/Drug-Search-4-2a9102bd41f16e8c40c9d8044d1dcb6f206ff80107cc269aa83d02ea683bc829.jpg","DDI-5.jpg":"/assets/linkouts/DDI-5-fa1c287946f4044094c723161577cb5ac631f9cd1217446e510dc79ace6cb94e.jpg","TH-1.jpg":"/assets/linkouts/TH-1-55a9077bb39e8c38a68c67b555b8091d21a9d41b1c21c7daed3fe53e6f9f3c97.jpg","TH-2.jpg":"/assets/linkouts/TH-2-1d488747fa4af00ab970a48dba0b228b054d166aa22c1760a310e2b72dd22589.jpg"})
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates